Evidence map›Paper›PMID 40055744›Full record

ArticleBreast cancer research : BCR2025

Preclinical evaluation of

Takeshi Usui, Tomohiro Miyake, Tadashi Watabe, Hiroki Kato, Yukie Yoshii, Sadahiro Naka, Kaori Abe, Misato Masuyama, Nanae Masunaga, Tetsuhiro Yoshinami and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Takeshi UsuiDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka, 565-0871, Japan.ORCID http://orcid.org/0009-0009-0510-6756
Tomohiro MiyakeDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka, 565-0871, Japan. t_miyake@onsurg.med.osaka-u.ac.jp.ORCID http://orcid.org/0000-0002-9362-9822
Tadashi WatabeDepartment of Nuclear Medicine and Tracer Kinetics, Osaka University Graduate School of Medicine, Osaka, Japan.
Hiroki KatoDepartment of Advanced Radioisotope Medicine, Institute for Radiation Sciences, Osaka University, Osaka, Japan.
Yukie YoshiiLinqmed Inc., Chiba, Japan.
Sadahiro NakaDepartment of Pharmacy, Osaka University Hospital, Osaka, Japan.
Kaori AbeDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Misato MasuyamaDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Nanae MasunagaDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Tetsuhiro YoshinamiDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Masami TsukabeDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Yoshiaki SotaDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Tomonori TaneiDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Masafumi ShimodaDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka, 565-0871, Japan.
Kenzo ShimazuDepartment of Breast and Endocrine Surgery, Osaka University Graduate School of Medicine, 2-2-E10 Yamada-oka, Suita, Osaka, 565-0871, Japan.

Funding

Japan Society for the Promotion of Science 22K07231
6 · The paper itself

Abstract

backgroundDespite advances in breast cancer imaging, reliable detection of sentinel lymph node (SLN) metastasis remains challenging. This study aimed to determine the ability of immuno-positron emission tomography (PET) using

methodsThe SLN metastasis model was established using the EGFR-strongly-expressing MDA-MB-468 breast cancer cell line. In this xenograft model, [

resultsAfter intravenous administration of [

conclusionsPET with intravenously administered [

Indexed as

Breast NeoplasmsCetuximabCopper RadioisotopesPositron-Emission TomographySentinel Lymph NodeAnimalsCell Line, TumorDisease Models, AnimalErbB ReceptorsFemaleFluorodeoxyglucose F18HumansLymphatic MetastasisMiceRadiopharmaceuticalsXenograft Model Antitumor AssaysCetuximabCopper-64Copper RadioisotopesEGFR protein, humanErbB ReceptorsFluorodeoxyglucose F18RadiopharmaceuticalsBreast cancerEpidermal growth factor receptorImmuno-PETSentinel lymph node metastasis

Identifiers

PMID40055744
PMCPMC11889786

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.